Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review.

[1]  C. Criscitiello,et al.  A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer. , 2022, Future oncology.

[2]  J. Grandis,et al.  IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer , 2021, Cancers.

[3]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[4]  D. Assad,et al.  Worldwide Prevalence of PI3K-AKT-mTOR Pathway Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis. , 2021, Critical reviews in oncology/hematology.

[5]  G. Wilson,et al.  Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer , 2020, Clinical and translational radiation oncology.

[6]  P. Boutros,et al.  TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma , 2020, Journal of experimental & clinical cancer research : CR.

[7]  A. Porgador,et al.  CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3Kα Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma , 2020, Journal of clinical medicine.

[8]  Y. Im,et al.  Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer , 2020, Clinical Cancer Research.

[9]  Yeon-Hee Park,et al.  A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer , 2020, Clinical Cancer Research.

[10]  Kohei Furukawa,et al.  Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab-resistant oral squamous cell carcinoma , 2020, Oncology reports.

[11]  Kai-Ping Chang,et al.  Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts , 2020, Cancers.

[12]  S. Bicciato,et al.  PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma , 2020, Clinical Cancer Research.

[13]  J. Grandis,et al.  HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma , 2019, Scientific Reports.

[14]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[15]  B. Rotblat,et al.  Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy. , 2019, JCI insight.

[16]  G. Mills,et al.  Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. , 2019, The Lancet. Oncology.

[17]  Jing Wang,et al.  PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition , 2019, Clinical Cancer Research.

[18]  P. Boutros,et al.  A controlled trial of HNSCC patient‐derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth , 2019, International journal of cancer.

[19]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[20]  Sourav Bandyopadhyay,et al.  Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. , 2018, Cancer research.

[21]  G. Wilson,et al.  Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer , 2018, Clinical and translational radiation oncology.

[22]  Ruud H. Brakenhoff,et al.  The molecular landscape of head and neck cancer , 2018, Nature Reviews Cancer.

[23]  S. Y. Kim,et al.  Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer. , 2018, Oral oncology.

[24]  H. Soares,et al.  Final report: A phase I trial of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer. , 2018 .

[25]  Dejan Juric,et al.  Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  B. Cho,et al.  ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma , 2018, Oncogene.

[27]  P. Lønning,et al.  Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.

[28]  R. Coletta,et al.  In vivo and in vitro effects of curcumin on head and neck carcinoma: a systematic review , 2017, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[29]  N. Lee,et al.  Phase Ib study of cetuximab + BYL719 + IMRT in stage III-IVB head and neck squamous cell carcinoma (HNSCC). , 2017 .

[30]  Sung-Bae Kim,et al.  Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. , 2017, The Lancet. Oncology.

[31]  Z. Chen,et al.  In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance , 2017, Molecular Cancer Therapeutics.

[32]  F. Penault-Llorca,et al.  Combination of phosphotidylinositol‐3‐kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer , 2017, Head & neck.

[33]  F. De Felice,et al.  New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors. , 2017, Oral oncology.

[34]  Xiao Jiang,et al.  Elevated autocrine chemokine ligand 18 expression promotes oral cancer cell growth and invasion via Akt activation , 2016, Oncotarget.

[35]  J. Baselga,et al.  Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations , 2015, Clinical Cancer Research.

[36]  G. Sica,et al.  Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers , 2015, Cancer Prevention Research.

[37]  S. Paik,et al.  Clinical trials outcomes of combined BKM120 and cetuximab compared to BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN). , 2015 .

[38]  S. Papish,et al.  Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program. , 2015 .

[39]  C. Van Waes,et al.  MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma , 2015, Clinical Cancer Research.

[40]  Angela Tam,et al.  AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. , 2015, Cancer cell.

[41]  C. Rudin,et al.  A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. , 2015, Oral oncology.

[42]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[43]  G. Milano,et al.  Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines , 2015, Investigational New Drugs.

[44]  James B. Mitchell,et al.  Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384 , 2014, Clinical Cancer Research.

[45]  R. Bianco,et al.  The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models , 2014, British Journal of Cancer.

[46]  John R. Bucher,et al.  Systematic Review and Evidence Integration for Literature-Based Environmental Health Science Assessments , 2014, Environmental health perspectives.

[47]  O. Olopade,et al.  Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition , 2013, Molecular oncology.

[48]  K. Wooley,et al.  Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma , 2011, British Journal of Cancer.

[49]  A. Jimeno,et al.  New phosphatidylinositol 3-kinase inhibitors for cancer , 2011, Expert opinion on investigational drugs.

[50]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[51]  A. Garden,et al.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[53]  Frank McCormick,et al.  High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. , 2005, Cancer research.

[54]  P. Massion,et al.  Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. , 2004, American journal of respiratory and critical care medicine.

[55]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[56]  A. Garden,et al.  Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? , 2004, Cancer.

[57]  M. J. Fry.  Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? , 2001, Breast Cancer Research.

[58]  John F. Timms,et al.  Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer , 2001 .

[59]  Chen-Yang Shen,et al.  PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.